Drug Profile
RPI MN
Alternative Names: pepteron; RPI-MNLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator ReceptoPharm
- Developer Bio Therapeutics; ReceptoPharm
- Class Antiretrovirals; Cobra neurotoxin proteins
- Mechanism of Action Nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis; HIV infections; Ocular herpes simplex
- Preclinical Herpes simplex virus infections
- Discontinued Rabies; Viral infections
Most Recent Events
- 22 Feb 2023 Preclinical development in Herpes-simplex-virus-infections is ongoing in USA (Parenteral) (ReceptoPharm pipeline, February 2023)
- 04 Feb 2021 Adverse events and efficacy data from phase I trial in HIV infections released by ReceptoPharm prior to February 2021 (ReceptoPharm pipeline, February 2021)
- 04 Feb 2021 RPI MN is still in phase I trials for Amyotrophic lateral sclerosis in USA (ReceptoPharm pipeline, February 2021)